Posts tagged oral
PureTech targeting dysfunctions in brain, gut, immune system

With eight clinical-stage studies underway, including two pivotal trials expected to readout later this year, PureTech Health (LSE:PRTC) is taking a novel approach to drug development, targeting serious diseases caused by dysfunctions in the brain, gut and immune system.

Read More
FeatureLeonard Zehrclinical study, clinical-stage, pivotal trial, PureTech, PureTech Health, LSE:PRTC, drug, drug development, diseases, chronic diseases, Bharatt Chowrira, Drs Chowrira, disease progression, slowing disease, halting disease, reversing disease, chronic, chronic disease, slow disease progression, detection, chronic disease treatment, biopharma, biopharmaceutical company, innovative approach, GI, gastrointestinal, obesity, bariatric surgery, Pharmaceuticals, obese, oral, oral therapy, oral therapies, GI tract, gastrointestinal tract, Gelesis100, Gelesis, transformative, transformative treatment, medical device, drug absorption, nutrient absorption, body weight loss, overweight, prediabetes, type 2 diabetes, obesity related diseases, fatty liver disease, osteoarthritis, cardiovascular, cardiovascular disease, non-alcoholic fatty liver disease, diabetes, diabetes therapy, Gelesis200, Gelesis 200, Gelesis 100, glycemic, glycemic control, liver disease, liver, proof-of-concept, preclinical, immune, aging population, innovation investment, immunosenescence, aging immune system, respiratory tract infections, pneumonia, influenza, mTOR, mTORC1, immune-enhance, Phase 2, peer-reviewed studies, RTB 101, cold, flu, Akili, ADHD, Attention Deficit Hyperactivity Disorder, Project:EVO, Alzheimer’s, Alzheimer's disease, Pfizer, digital medicine platform, cognitive science, Adam Gazzaley, Dr. Adam Gazzaley, UCSF, Dr. Gazzaley, elderly, elder patients, ADHD treatment, Internation Conference on Clinical Trails for Alzheimer's disease, pipeline, LSE, PRTC
In conversation with Chiara Russo

As a specialty pharmaceuticals analyst with Cantor Fitzgerald for the past 2 1/2 years, Chiara Russo covers developmental-stage companies that are on the cusp of changing the medical landscape as we know it. A philosophy major with an MBA from the Olin School of Business at Babson College, Ms. Russo was a R&D innovation consultant for Cubist Pharmaceuticals before becoming a sell-side equity research analyst. On the Street, she has been a research associate at ThinkEquity and VP and specialty pharmaceuticals analyst at Janney Montgomery Scott. In this interview with, Ms. Russo discusses industry trends and some of the stocks she likes.

Read More
IntelGenx sees 2017 milestones as transformational

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has multiple milestones on tap this year with its oral film drug delivery platform, VersaFilm, as it continues building strategic partnerships in the pharmaceutical industry.

Read More
Braeburn taking path as pill-free pharma company

Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse and non-compliance.

“This is the way of the future,” Behshad Sheldon, president and CEO, says in an interview with “In 10 years, there will be dozens and dozens of drug products available as long-acting injectables and implantables.”

Read More
Revive readies key clinical studies in gout and kidney stones

Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares.

“We believe that the Phase 2b data in gout will be a partner-enabling study with a large pharmaceutical company,” CEO, Fabio Chianelli, says in an interview with, noting that the clinical trial should be completed by the end of this year.

Mr. Chianelli explains that Bucillamine is an oral, small molecule drug with a 30-year history as a first-line treatment for rheumatoid arthritis in Japan and Korea. It is sold under the brand name, Rimatil. The drug’s safety has been established in 7,000 subjects from clinical studies and post-marketing evaluations.

Read More